Zacks Investment Research upgraded shares of Collegium Pharmaceutical Inc. (NASDAQ:COLL) from a sell rating to a hold rating in a research note released on Wednesday morning.

According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “

COLL has been the subject of a number of other reports. Jefferies Group reiterated a buy rating on shares of Collegium Pharmaceutical in a report on Thursday, September 22nd. Needham & Company LLC reiterated a buy rating and set a $30.00 price objective on shares of Collegium Pharmaceutical in a report on Wednesday, September 14th. Gabelli assumed coverage on shares of Collegium Pharmaceutical in a report on Tuesday, September 13th. They set a buy rating and a $25.00 price objective for the company. Finally, Piper Jaffray Cos. set a $23.00 price target on shares of Collegium Pharmaceutical and gave the stock a buy rating in a report on Thursday, August 11th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $27.60.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL) opened at 18.13 on Wednesday. The firm has a 50-day moving average of $13.29 and a 200 day moving average of $14.54. Collegium Pharmaceutical has a 12-month low of $8.24 and a 12-month high of $30.58. The company’s market capitalization is $426.56 million.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.29. Analysts forecast that Collegium Pharmaceutical will post ($3.86) EPS for the current fiscal year.

In other news, Director John A. Fallon bought 2,375 shares of the firm’s stock in a transaction that occurred on Friday, August 12th. The shares were acquired at an average price of $10.59 per share, with a total value of $25,151.25. Following the acquisition, the director now owns 2,375 shares of the company’s stock, valued at approximately $25,151.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 37.93% of the company’s stock.

A number of hedge funds have recently bought and sold shares of COLL. TPG Group Holdings SBS Advisors Inc. raised its stake in Collegium Pharmaceutical by 4.9% in the second quarter. TPG Group Holdings SBS Advisors Inc. now owns 1,389,863 shares of the specialty pharmaceutical company’s stock worth $16,470,000 after buying an additional 64,600 shares during the period. Franklin Resources Inc. raised its stake in Collegium Pharmaceutical by 8.9% in the second quarter. Franklin Resources Inc. now owns 903,602 shares of the specialty pharmaceutical company’s stock worth $10,708,000 after buying an additional 74,003 shares during the period. FMR LLC raised its stake in Collegium Pharmaceutical by 43.2% in the second quarter. FMR LLC now owns 802,373 shares of the specialty pharmaceutical company’s stock worth $9,508,000 after buying an additional 242,073 shares during the period. BlackRock Fund Advisors raised its stake in Collegium Pharmaceutical by 29.3% in the second quarter. BlackRock Fund Advisors now owns 650,474 shares of the specialty pharmaceutical company’s stock worth $7,708,000 after buying an additional 147,461 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its stake in Collegium Pharmaceutical by 38.2% in the second quarter. Massachusetts Financial Services Co. MA now owns 500,309 shares of the specialty pharmaceutical company’s stock worth $5,929,000 after buying an additional 138,305 shares during the period. 62.13% of the stock is currently owned by institutional investors and hedge funds.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

5 Day Chart for NASDAQ:COLL

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.